Ryzneuta Market Report 2026

Ryzneuta Market Overview

• The Ryzneuta market growth in the historic period has been driven by growth in chemotherapy treatment volumes, adoption of colony-stimulating factors • Market expansion is supported by expansion of long-acting biologic drug pipelines, rising demand for outpatient cancer care support • Growth Driver: Surge In Prevalence Of Cancer Driving Market Growth Due To Rising Demand For Personalized Oncology Treatments And Advances In Immunotherapy • Market Trend: Evive Biotech and Acrotech Biopharma Launch Ryzneuta In Germany To Enhance Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ryzneuta Market?

Ryzneuta (efbemalenograstim alfa) is a long-acting granulocyte colony-stimulating factor (G-CSF) used to reduce the risk of infection in adults with non-myeloid malignancies undergoing chemotherapy. It works by stimulating the production of neutrophils, a type of white blood cell essential for fighting infections. The main types of indications in ryzneuta are chemotherapy-induced neutropenia, cyclic neutropenia, idiopathic neutropenia, and congenital neutropenia. Chemotherapy-induced neutropenia is a condition where chemotherapy reduces neutrophil levels, increasing the risk of severe, life-threatening infections due to weakened immune defense. It is available in both parenteral and oral forms, and distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. It caters to various end users such as hospitals, specialty clinics, home healthcare, and research and academic institutes.

What Is The Ryzneuta Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of long-acting biologic drug pipelines, rising demand for outpatient cancer care support, growth of personalized oncology treatment regimens, increasing focus on reducing hospitalization rates, supportive reimbursement for oncology biologics. Major trends in the forecast period include increasing use of long-acting g-csf therapies, rising focus on chemotherapy supportive care, expansion of infection risk reduction protocols, improved oncology treatment outcomes, enhanced patient convenience and compliance.

Global Ryzneuta Market Segmentation

1) By Indication: Chemotherapy-Induced Neutropenia, Cyclic Neutropenia, Idiopathic Neutropenia, Congenital Neutropenia 2) By Route Of Administration: Parenteral, Oral 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End User: Hospitals, Specialty Clinics, Home Healthcare, Research And Academic Institutes

What Is The Driver Of The Ryzneuta Market?

The increasing prevalence of cancer is expected to propel the growth of the ryzneuta market going forward. Cancer is a group of diseases characterized by the uncontrolled growth of abnormal cells that can form tumors, invade nearby tissues, and spread to other parts of the body through the bloodstream or lymphatic system. The increasing prevalence of cancer can be attributed to factors such as an aging population, unhealthy lifestyle choices, environmental exposures, genetic predispositions, improved detection methods, and chronic inflammation or infections. Ryzneuta helps cancer by targeting and inhibiting specific cancer cell growth mechanisms, thereby enhancing the body’s immune response and improving treatment outcomes for certain cancers, such as non-Hodgkin lymphoma. For instance, in Febuary 2024, according to World Health Organisation (WHO), a US-based specialized agency, cancer incidence is projected to rise sharply, with annual new cases expected to increase from an estimated 20 million in 2022 to more than 35 million by 2050, representing approximately 77% growth over the period. Therefore, increasing prevalence of cancer is driving the growth of the ryzneuta industry.

Key Players In The Global Ryzneuta Market

Major companies operating in the ryzneuta market are Evive Biotech Private Limited, Acrotech Biopharma LLC

Global Ryzneuta Market Trends and Insights

Key companies in the ryzneuta market are developing innovative drug development, such as efbemalenograstim alfa injections, to address unmet medical needs, enhance treatment efficacy, and improve patient outcomes. Efbemalenograstim alfa injection is a long-acting granulocyte colony-stimulating factor (G-CSF) used to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy. For instance, in November 2024, Evive Biotech Private Limited, a Singapore-based biopharmaceutical company, partnered with Acrotech Biopharma LLC, a US-based pharmaceutical company, and launched Ryzneuta in Germany. This innovative biologic treatment is designed to stimulate the production of white blood cells, helping to reduce the risk of infection in patients undergoing chemotherapy or other treatments that suppress immune function. The product is expected to play a key role in improving patient outcomes, enhancing their recovery process, and offering an alternative to existing treatments with unique benefits.

What Are Latest Mergers And Acquisitions In The Ryzneuta Market?

In November 2023, Acrotech Biopharma LLC, a US-based pharmaceutical company specializing in the development and commercialization of innovative proprietary medications, partnered with Evive Biotech Private Limited. This collaboration was aimed at the commercialization of Ryzneuta (Efbemalenograstim alfa), a treatment for chemotherapy-induced neutropenia (CIN), in the United States. Under the terms of the partnership, Evive Biotech granted Acrotech Biopharma exclusive rights to market and distribute the drug in the US, further strengthening both companies' presence in the oncology therapeutics market. Evive Biotech Private Limited, a Singapore-based biopharmaceutical company devoted to developing a portfolio of novel biological therapies.

Regional Insights

North America was the largest region in the ryzneuta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Ryzneuta Market?

The ryzneuta market consists of sales of injectable formulations, combination therapies, pre-filled syringes, autoinjectors, and biosimilar alternatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ryzneuta Market Report 2026?

The ryzneuta market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ryzneuta industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.